Market Overview

UPDATE: Oppenheimer Downgrades Rigel Pharmaceuticals on Disappointing Ph.III OKSIRA-2/3 Studies

Share:

In a report published on Tuesday, Oppenheimer analyst David Ferreiro downgraded Rigel Pharmaceuticals (NASDAQ: RIGL) from Outperform to Perform and removed the price target of $10.

In the report, Oppenheimer noted, "As in the prior OKSIRA-1 results (methotrexate-failures), fostamatinib showed significantly higher ACR20 rates over placebo at 100mg BID in both studies, but these results appear suboptimal vs. current injectable RA therapies. While AZN did not reveal more critical ACR50 and 70 rates, it has decided to return fostamatinib rights to Rigel based on its review of the totality of the ph.III OSKIRA results. We now believe fostamatinib may no longer be viable commercially and at best addresses a small salvage opportunity in RA."

Rigel Pharmaceuticals closed on Monday at $4.53.

Latest Ratings for RIGL

DateFirmActionFromTo
May 2020JP MorganMaintainsOverweight
Dec 2019BMO CapitalMaintainsOutperform
Nov 2019Cantor FitzgeraldMaintainsOverweight

View More Analyst Ratings for RIGL
View the Latest Analyst Ratings

 

Related Articles (RIGL)

View Comments and Join the Discussion!

Posted-In: David Ferreiro OppenheimerAnalyst Color Downgrades Analyst Ratings

Latest Ratings

StockFirmActionPT
BFYTB. Riley FBRDowngrades31.0
HBICredit SuisseUpgrades15.0
FISGoldman SachsInitiates Coverage On164.0
INNRaymond JamesMaintains7.5
RHPRaymond JamesMaintains45.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com